Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04899180 · ClinicalTrials.gov registry record · Early Phase 1

Prevalence of Transthyretin Cardiac Amyloidosis in Clinically Significant Aortic Stenosis

A Early Phase 1 study of Aortic Stenosis and Transthyretin Amyloidosis, sponsored by Mayo Clinic.

Completed
Registry status
Early Phase 1
Development phase
4
Enrollment target
1
Study location

NCT04899180 is a Early Phase 1 study of Aortic Stenosis and Transthyretin Amyloidosis that has completed, run by Mayo Clinic. The registered enrollment target is 4 participants, below the 1,362-participant average among 26 other Aortic Stenosis trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04899180, a Early Phase 1 study of Aortic Stenosis and Transthyretin Amyloidosis, has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
Early Phase 1
Development phase
4 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine the prevalence of transthyretin cardiac amyloidosis (TTR-CA) among patients with moderate and severe aortic stenosis in Southeast Minnesota using 99mTc-PYP single-photon positive emission computed tomography with computed tomography (SPECT/CT).

Interventions

  • DRUG 99mTc-PYP

Study Locations (1)

Minnesota

  • Mayo Clinic in Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 4 participants
Start Date 2023-07-14
Est. Completion 2024-01-05
Phase Early Phase 1

Sponsor

Mayo Clinic

2,844 total trials

What the Registry Record Tells You About NCT04899180

The ClinicalTrials.gov registry entry for NCT04899180 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,362-participant average among 26 other Aortic Stenosis trials with a reported enrollment target (100% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Aortic Stenosis appearing as the primary indexed condition, and to 1 intervention - of which 99mTc-PYP is the first listed.

NCT04899180 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT04899180 about?

NCT04899180 is a clinical study titled "Prevalence of Transthyretin Cardiac Amyloidosis in Clinically Significant Aortic Stenosis". The purpose of this study is to determine the prevalence of transthyretin cardiac amyloidosis (TTR-CA) among patients with moderate and severe aortic stenosis in Southeast Minnesota using 99mTc-PYP single-photon positive emission computed tomography with computed tomography (SPECT/CT).

What is the current status of trial NCT04899180?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 4 participants. The study started on 2023-07-14. Estimated completion is 2024-01-05.

What conditions does trial NCT04899180 study?

This clinical trial studies the following conditions: Aortic Stenosis, Transthyretin Amyloidosis, Transthyretin Cardiac Amyloidosis, Transthyretin Amyloid Cardiomyopathy.

What interventions are being tested in trial NCT04899180?

The interventions under investigation include: 99mTc-PYP (DRUG).

Who is sponsoring clinical trial NCT04899180?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04899180 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Aortic Stenosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.